an undergraduate student at Northwestern University? a high school student thinking about where to go to college? interested and strong in mathematics and data analysis? thinking about a career — or a ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...

The latest local and national news updates. Breaking news and hard-hitting talk - Stephen Nolan gets you talking about the big stories of the day. Call Stephen on 03030 80 55 55 (standard geographic ...

Lee and the Breakfast team have plenty of laughs and all you need to start your day.